

## The Myth of Schizophrenia as a Progressive Brain Disease

Robert B. Zipursky<sup>\*1</sup>, Thomas J. Reilly<sup>2</sup>, Robin M. Murray<sup>2</sup>

<sup>1</sup>Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada; <sup>2</sup>Department of Psychosis Studies, Institute of Psychiatry, Kings College, De Crespigny Park, London, UK

\*To whom correspondence should be addressed; St Joseph's Healthcare Hamilton, 100 West 5th Street, Hamilton, Ontario L8N3K7, Canada; tel: 905-522-1155 x 36250, fax: 905-381-5633, e-mail: [bzipursk@stjosham.on.ca](mailto:bzipursk@stjosham.on.ca)

Schizophrenia has historically been considered to be a deteriorating disease, a view reinforced by recent MRI findings of progressive brain tissue loss over the early years of illness. On the other hand, the notion that recovery from schizophrenia is possible is increasingly embraced by consumer and family groups. This review critically examines the evidence from longitudinal studies of (1) clinical outcomes, (2) MRI brain volumes, and (3) cognitive functioning. First, the evidence shows that although approximately 25% of people with schizophrenia have a poor long-term outcome, few of these show the incremental loss of function that is characteristic of neurodegenerative illnesses. Second, MRI studies demonstrate subtle developmental abnormalities at first onset of psychosis and then further decreases in brain tissue volumes; however, these latter decreases are explicable by the effects of antipsychotic medication, substance abuse, and other secondary factors. Third, while patients do show cognitive deficits compared with controls, cognitive functioning does not appear to deteriorate over time. The majority of people with schizophrenia have the potential to achieve long-term remission and functional recovery. The fact that some experience deterioration in functioning over time may reflect poor access, or adherence, to treatment, the effects of concurrent conditions, and social and financial impoverishment. Mental health professionals need to join with patients and their families in understanding that schizophrenia is not a malignant disease that inevitably deteriorates over time but rather one from which most people can achieve a substantial degree of recovery.

*Key words:* MRI/cognition/outcome/prognosis/remission/recovery

### Introduction

Schizophrenia is a leading cause of disability worldwide.<sup>1</sup> Kraepelin originally characterized the illness as having a course that led almost inevitably to severe cognitive and

behavioral decline,<sup>2</sup> and many clinicians and neuroscientists still consider it to be a progressive brain disease that leads to chronicity and social incapacity.<sup>3,4</sup> This view has been reinforced by recent neuroimaging studies that have shown supposedly “progressive” changes in brain structure.<sup>5,6</sup> A progressive neuropathological process would provide a straightforward paradigm to understand the relationship between pathophysiology and a poor illness outcome.

This idea of schizophrenia as a progressive disease of the brain has also been an important part of the rationale for developing early intervention services. Indeed, the notion that psychosis itself may be toxic to the brain<sup>7</sup> provided a major impetus for programs designed to minimize the duration of untreated psychosis (DUP) in order to prevent further brain tissue loss.<sup>8</sup> However, the widespread development over the past 2 decades of specialized clinical programs to treat young people experiencing a first episode of psychosis (FEP) has also provided new opportunities to evaluate the outcome of the illness together with the course of structural brain differences and cognitive deficits. In this article, we will review the evidence concerning these 3 aspects of the illness in order to evaluate whether it is consistent with the view of schizophrenia as a progressive brain disease.

### Definitions

In order to characterize the outcome from schizophrenia, it is necessary to define the patient samples and measures of outcome found in different studies. Longitudinal studies that have followed patients after their FEP vary in their inclusion criteria. Some studies of first episode schizophrenia (FES) have included patients meeting criteria for schizophrenia or schizoaffective disorder,<sup>9,10</sup> while others have included those meeting criteria for schizophreniform disorder.<sup>11</sup> In this review, studies using these more narrow definitions will be referred to as studies of FES. Those studies that have included other psychotic disorders such as

delusional disorder, brief psychotic disorder, and psychosis not otherwise specified, but excluded patients whose psychosis is due to a primary affective disorder, will be referred to as studies of FEP. Studies of FES and FEP also vary in the age range of subjects, the duration of time that the person has been ill prior to involvement in the study, and the duration of treatment prior to entering the study. In discussing the outcome from a FES or FEP, we have taken an inclusive approach because many studies do not provide specific details about age and duration criteria utilized.

Definitions for remission also vary considerably.<sup>12,13</sup> Remission criteria have typically required that positive symptoms be reduced to a mild level of severity, while criteria vary for the severity of negative symptoms and duration required to meet the threshold for remission.<sup>9</sup> The term “remission” will be used here to refer to patients whose positive symptoms have diminished to levels considered to be mild or lower in the presence of negative symptoms that are no greater than moderate in severity. The terms “functional recovery” and “recovery” are also used in this review. “Functional recovery” refers to the achievement of an adequate level of social and vocational functioning that involves appropriate role functioning, capacity for independent living, and social interactions at a regular frequency.<sup>10</sup> A range of definitions of the term “recovery” have been used in the schizophrenia literature and vary considerably between researchers, clinicians, and consumers.<sup>12,14</sup> The term “recovery” is used in this article to refer to levels of social and vocational functioning that are within the normal range together with a remission of psychiatric symptoms.<sup>10,12</sup>

## Outcome of Schizophrenia

Longitudinal follow-up studies of patients diagnosed as having schizophrenia have consistently found that about 40% achieve social or functional recovery.<sup>15–17</sup> While this finding in itself casts doubt on whether schizophrenia is inherently progressive, there is no question that schizophrenia can be a very disabling illness that causes many of those affected to suffer a substantial decline in their functioning and in their ability to realize their full potential. Two questions arise concerning this disability. First, does it result from stable deficits that are established early in the illness or from a progressive decline in functioning over the course of the illness? Second, does any functional decline reflect the impact of underlying biological disease mechanisms or rather the cumulative impact of adverse social factors and their interaction with the patient? To address these questions, it is instructive to begin by considering whether patients who experience a FES or FEP can achieve periods of remission and recovery over the course of their illness.

### Remission

With appropriate care, including the skillful prescription of antipsychotic medication, the early years following a

FEP are not typically periods of decline but rather of substantial ongoing improvement in symptom severity and functioning.<sup>17–19</sup> Lieberman *et al* reported that 83% of patients with a FES experience a remission in psychotic symptoms within the first year of treatment.<sup>9</sup> This is comparable to estimates of rates of remission of 70%–74% for patients with a FEP.<sup>18,20,21</sup> These high rates of remission may in part reflect the effects of the assertive treatment received in research-intensive services and specialized FEP services, as well as the sampling approaches used. However, the evidence to date suggests that those patients who achieve remission after their first episode are, on average, able to maintain similar rates of remission over the longer term as well; ie, the proportion relapsing is matched by others remitting.<sup>11</sup> Thus, Girgis *et al* described the outcome of 160 Chinese patients with a FES who were randomized to clozapine or chlorpromazine for 2 years and then followed naturalistically for 7 years.<sup>11</sup> Between years 2 and 9, the percentage of patients rated as being in remission remained stable at 78% irrespective of their initial assignment to clozapine or chlorpromazine.

It is true that those who have had a FES run a high risk of relapse. Robinson *et al* reported that 82% of patients who achieved a remission from their FES experienced a relapse within 5 years, with comparable percentages of relapsed patients going on to have a second and third relapse.<sup>22</sup> Those who discontinue medications in the early years are at especially high risk with reports of the percentage relapsing within 1 year as high as 78%<sup>23</sup> compared with rates of 0%–12% for those who remain on antipsychotic medications.<sup>24–27</sup> Thus, while remitted patients who discontinue maintenance treatment have high relapse rates, those who are adherent have an equally high likelihood of remaining in remission. Adherence rates may be enhanced by efforts to better inform patients of the risk and consequences of relapse and by optimizing pharmacologic management to minimize bothersome side effects.

### Functional Recovery

Unfortunately, one cannot assume that patients who are in remission will have an adequate quality of life. Rates of functional recovery are lower than rates of remission.<sup>10,15–17,28</sup> In a systematic review of outcomes following a FEP, Menezes *et al*<sup>16</sup> found that approximately 40% of patients achieved functional recovery whether the follow-up period was less than, or greater than, 2 years. The percentage of patients considered to have a “poor outcome” was also estimated to remain stable at approximately 25%.<sup>16</sup> These estimates are in keeping with the results of Lambert *et al*<sup>15</sup> who carried out a 3-year follow-up study of 369 patients with a FES and found that the percentage considered to be in a “functional remission” (defined as the fulfillment of occupational status, independent living, and social relationships)

remained stable at approximately 40% at 1-year and 3-year follow-up points. Similarly, Henry et al<sup>29</sup> found that 30.5% of 428 patients assessed a median of 7.4 years after their FEP met criteria for social-vocational recovery.

As with remission, however, the proportion recovered does not appear to either increase or decrease with time. Bertelsen et al found that only 17% of patients with a first episode of illness within the schizophrenia spectrum were considered recovered after 2 years, comparable to the rate of 18% found at 5 years.<sup>19</sup> Thus, while rates of recovery may vary across samples and with different criteria for recovery, they appear to remain stable within a given sample at least for the first 2–5 years of illness. The multicentre International Study of Schizophrenia supported by the World Health Organization found that the percentage time spent psychotic in the first 2 years of follow-up after a FES was the best predictor of symptom and disability scores at 15-year follow-up.<sup>30</sup> Thus patients who do not experience remission and are doing poorly in the first 2 years of illness are likely to be part of the 25% of patients reported to have a poor outcome over the longer term. In summary, rates of symptomatic and functional remission and rates of poor outcome appear to be relatively stable even over extended periods of follow-up. This pattern of stability would not occur in an illness that is by nature progressive.

There is little reason to believe that clinical deterioration that is often observed in patients with schizophrenia is an inevitability. Rather it may be a reflection not only of nonadherence and resulting relapses but also of the consequences of other critical determinants of health such as poverty, homelessness, unemployment, and lack of social support, as well as other comorbidities, that all too often complicate the course of schizophrenia.<sup>31</sup>

#### *Why Do Clinicians Have Such a Pessimistic View?*

The view that most people with schizophrenia become markedly disabled continues to be held by many clinicians. In their seminal article, “The Clinician’s Illusion”, Cohen and Cohen<sup>32</sup> cited schizophrenia as an example of an illness for which the Clinician’s Illusion is particularly relevant. The Clinician’s Illusion is, “the attribution of the characteristics and course of those patients who are currently ill to the entire population contracting the illness.” This illusion occurs because clinicians typically care for those patients currently suffering from the illness (ie, a prevalence sample), rather than of all those who have ever contracted the illness (ie, an incidence sample). Patients who are remitted or well stabilized are less likely to be seen in specialized psychiatric services, and if they are seen at all, it is more likely to be by their family doctor. Cohen and Cohen demonstrated that the likelihood that a patient will appear in such specialized clinics (ie, in a prevalence sample) is proportional to the duration of their illness. As a result, prevalence samples are greatly

biased toward those who have been ill for many years, while those who have had brief periods of illness are underrepresented.

Cohen and Cohen also pointed out another important biasing artifact known as “Berkson’s Fallacy”: “those who have other disabilities that are not causally connected to the condition being investigated are more likely to enter the formal treatment system.” As a result, patients may have clusters of problems that adversely contribute to their outcome but are not consequent upon the condition being treated. It is common in specialized schizophrenia clinics to see patients with concurrent problems of low intellectual functioning and developmental disabilities, as well as with mood, anxiety personality, and substance use disorders. The high prevalence of these problems in a specialized clinic does not argue for these difficulties being a direct consequence of schizophrenia. Rather, individuals with these problems in addition to having schizophrenia are more likely to find themselves in such specialized clinics. Each of these conditions can be very disabling on their own, and when they occur together with schizophrenia, the net impact will be more severe disability. However, it may not be the natural course of schizophrenia, the principal factor responsible for the poor outcome. Thus, the fact that clinical researchers who write about schizophrenia mainly see patients who are profoundly disabled is more likely to reflect referral and sampling biases than the progressive nature of schizophrenia per se.

#### **The Search for Progressive Brain Changes**

Researchers have sought to identify structural brain changes in schizophrenia since the time of Kraepelin.<sup>2</sup> Postmortem<sup>33</sup> and pneumoencephalographic studies<sup>34,35</sup> provided support for the presence of atrophic brain changes in some patients with chronic schizophrenia. However, the opportunity to systematically investigate brain structure emerged in the 1970s and 1980s. Computed tomography (CT) revealed that patients with schizophrenia on average had larger intracranial cerebrospinal fluid (CSF) volumes, including larger lateral ventricles<sup>36,37</sup> and cortical sulci.<sup>38,39</sup> Subsequent MRI studies demonstrated widespread deficits in gray matter volumes<sup>40,41</sup> and white matter volumes.<sup>42</sup> The magnitude of these group differences was observed to be greater for more chronically ill patients.<sup>43</sup> From the outset, both CT and MRI studies sought to demonstrate associations between illness duration and the magnitude of CSF and gray matter volumes, but with little success.<sup>40,44</sup>

MRI studies confirmed significant brain volume reductions in patients with chronic schizophrenia and also demonstrated their presence in patients presenting with their FES or FEP.<sup>45,46</sup> However, the magnitude of the effects observed for CSF increases and gray matter decreases in the early phase of the illness has been found to be

modest relative to those observed in more chronically ill patients.<sup>45-47</sup> The possibility that this difference might be consistent with a progressive neuropathological process has been enticing. Alternative hypotheses, that this difference reflects a sampling bias or the effects of medications and other factors secondary to the illness, have received less attention to date. If patients who have more striking differences in CSF and gray matter volumes at the time of their first episode are more likely to have a poor outcome,<sup>48-53</sup> then such patients will have an increased likelihood of being represented in samples recruited from services for chronically ill patients.<sup>54</sup> Patients with a poor outcome may also be more likely to have neurodevelopmental problems and/or substance abuse that may independently be associated both with similar structural brain changes and with worse outcome. Whether the differences in the magnitude of structural brain changes observed in first episode compared with more chronically ill patients are due to progressive changes or sampling effects is best addressed through longitudinal studies.

#### *Longitudinal Studies and the Effects of Antipsychotic Medication*

Longitudinal MRI studies have now shown that brain tissue volumes decrease and CSF volumes increase over time to a greater degree in patients with schizophrenia than control subjects.<sup>47,55,56</sup> However, there is now compelling evidence that antipsychotic medications have an important role in contributing to these “progressive” changes.<sup>57,58</sup> Lieberman *et al*<sup>59</sup> followed patients treated with either olanzapine or haloperidol for a FEP for 2 years; patients treated with haloperidol but not olanzapine had worsening deficits in gray matter volumes that were already apparent after 12 weeks of treatment. It was unclear whether the relative volume reductions seen in the haloperidol-treated group reflected a disease process that was ameliorated by olanzapine but not haloperidol, a drug effect caused by haloperidol but not olanzapine, an increase in relative tissue volume related to the weight gain and metabolic effects associated with olanzapine, or a statistical artifact caused by sample attrition.<sup>60</sup>

Ho *et al*<sup>61</sup> have now demonstrated an association between antipsychotic treatment and brain volume reductions in patients ascertained with a FES who were scanned longitudinally over an average of 7.2 years. Antipsychotics were associated with decreases in gray- and white matter volumes with higher doses resulting in greater decreases.<sup>61</sup>

That antipsychotic medications can result in reductions in brain tissue volumes has been put beyond doubt by animal studies.<sup>62,63</sup> Both haloperidol and olanzapine led to decreases in gray matter and white matter in macaque monkeys treated chronically for 17–27 months.<sup>62</sup> Like the brain changes described in schizophrenia, these deficits were diffusely distributed across the frontal, parietal, temporal, occipital, and cerebellar areas. Similar findings

have been demonstrated using postmortem samples and *ex vivo* MRI using chronic doses of haloperidol and olanzapine in chronically treated rats.<sup>63</sup> Animal models provide the opportunity to better characterize the effects of antipsychotics on brain tissue and to determine the extent to which they may be progressive or reversible. Indeed, Vernon *et al*<sup>64</sup> have shown that MRI scans normalize in rats following withdrawal of the antipsychotic. Results from a longitudinal study of patients with a FES in Sao Paulo, Brazil, suggests that differences observed at the time of the first episode (after the initiation of antipsychotics) may also be reversible to some degree with medication discontinuation.<sup>65</sup>

#### *Effects of Substance Use*

Recent studies have reported that cannabis<sup>66-68</sup> and cigarette smoking<sup>69</sup> are associated with MRI findings of diminished brain tissue volumes in psychotic and nonpsychotic populations. Rates of cannabis use and smoking are much higher in patients who develop schizophrenia and may contribute to the presence of brain volume differences at the time of the FEP.<sup>70</sup> Rais *et al*<sup>67</sup> found that cannabis-using patients who were followed for 5 years after a FES had greater losses in gray matter volumes and increases in lateral ventricle volumes than patients who were not abusing cannabis. Alcohol is also known to lead to reduction in brain tissue volumes<sup>71-73</sup> and to compound the differences observed in patients with schizophrenia.<sup>71</sup> That cannabis, alcohol, and smoking may all contribute to the magnitude of gray matter deficits observed in patients with schizophrenia is supported by recent findings by Stone *et al*<sup>74</sup> who found that at low to moderate levels, all were associated with lower gray matter volumes in individuals at high risk of psychosis and in healthy controls.

#### *Effects of Lifestyle*

Many patients with schizophrenia have a sedentary lifestyle that may also contribute to the deficits in brain tissue volumes observed. Colcombe *et al*<sup>75</sup> found that aerobic exercise increased gray matter and white matter volumes in elderly community volunteers who had been sedentary. This is consistent with animal studies, which have demonstrated that exercise can increase new capillary formation, dendritic growth, and new cell production in the hippocampus.<sup>76,77</sup> Pajonk *et al*<sup>78</sup> carried out a randomized controlled trial of the effects of exercise and showed that increased physical activity leads to increases in hippocampal volumes in both patients with schizophrenia and healthy controls.

#### *Stress and the Hypothalamic-Pituitary-Adrenal Axis*

The elevated glucocorticoid levels associated with chronic stress that patients with schizophrenia manifest may also contribute to the smaller brain tissue volumes observed.

Effects of stress and glucocorticoids on hippocampal and ventricular volumes have been demonstrated in animal models and in humans with Cushing's syndrome,<sup>79</sup> and these are known to be at least partially reversible.<sup>80,81</sup> In patients with a FEP, cortisol levels have been found to be raised and to correlate inversely with hippocampal volumes.<sup>82</sup>

#### *Duration of Untreated Psychosis*

If psychosis were in some way toxic to the brain, as Wyatt suggested,<sup>7</sup> then one would predict that there would be an association between the DUP and the magnitude of structural brain differences, particularly if the baseline MRI scans were obtained prior to treatment with antipsychotic medication. DUP has been found to be correlated with brain tissue volumes in some studies<sup>8,83–86</sup> but not in others.<sup>44,45,87</sup> Moreover, the direction of causality that underlies any association remains to be established because greater deficits in brain tissue volumes in those with greater DUP could reflect a more insidious onset of psychosis in those patients with greater longstanding deficits in brain tissue volumes.<sup>84</sup> Certainly, there has been no evidence to support the idea that longer DUP initiates a process of progressive and continuing brain change.

#### **Cognitive Studies**

There is now an extensive literature characterizing the cognitive deficits of patients with schizophrenia. The deficits reported typically fall between 1 and 2 standard deviations below the mean of healthy controls.<sup>88,89</sup> Cognitive deficits in patients with schizophrenia are associated with inability to function in the community<sup>90</sup> and, as a result, have been the focus of specific clinical interventions.<sup>91</sup> Measures of cognitive functioning have been shown to correlate with measures of brain structure in patients with schizophrenia and healthy controls.<sup>92–95</sup> If progressive brain tissue loss occurs over the course of schizophrenia, one might predict that this would be accompanied by progressive deterioration in cognitive functioning. The latter does not appear to be the case.<sup>96,97</sup>

#### *The Time Course of Cognitive Deficits*

When cognitive deficits are first present and whether there is some stage of the illness during which they progress have been areas of intensive study.<sup>98,99</sup> Cognitive deficits have been clearly demonstrated at the time of the FEP.<sup>89,98,100</sup> Cognition has been demonstrated to remain stable or improve<sup>96,101–103</sup> rather than deteriorate following a FEP. The improvement reported in some studies may reflect practice effects rather than real improvement.<sup>104</sup> Nevertheless, there is a consensus that this improvement plateaus following a FEP or FES, after which cognition does not worsen over time beyond what can be expected with normal aging.<sup>97,99,102</sup> Whether elderly patients with

schizophrenia may experience a phase of cognitive decline that is of greater slope than that observed in otherwise healthy people<sup>105,106</sup> remains a possibility that requires further investigation.

Cognitive deficits are present in a proportion of children who later develop schizophrenia.<sup>107–110</sup> Meta-analyses have found that children who later develop schizophrenia are 0.4–0.5 standard deviations below the population average on intelligence quotient (IQ).<sup>111,112</sup> This is considerably smaller than the deficits described in patients at the time of their FES, and it raises the question of whether there is an active period prior to the first episode in which further decline occurs. Longitudinal data from a large US birth cohort have provided evidence that cognitive deficits are present when assessed at age 7 in children who have gone on to develop schizophrenia as adults, but were substantially larger on some measures when reassessed at age 35.<sup>98</sup> Using a follow-back design with patients presenting with a FES, Bilder et al<sup>113</sup> found that individuals who had a FES had deficits in school performance that were apparent in the first grade and increased substantially in magnitude when retested in the 12th grade. While these studies provide support for a relative decline in cognitive performance in individuals who subsequently develop schizophrenia compared with controls, it was not initially clear from these studies whether the increasing gap in cognitive performance reflects an absolute decline in those who go on to develop schizophrenia.

The Dunedin Multidisciplinary Health and Development Study provided the opportunity to investigate the trajectory of childhood cognitive functioning in individuals subsequently diagnosed with schizophrenia.<sup>114</sup> Cognitive testing was administered at age 7, 9, 11, and 13 years; results did not show any absolute decline in cognition but instead showed 2 interrelated problems, an early static deficit and then a developmental lag. Children destined to develop schizophrenia entered primary school struggling with verbal reasoning and then fell further behind their peers in attention and working memory as they got older. While it cannot be ruled out that the group differences may have been due to other comorbid disorders in the group of children who went on to develop schizophrenia as adults, the results do not suggest that this group experienced any absolute deterioration in cognitive functioning. This is consistent with the findings of Russell et al who demonstrated that individuals who had attended a child psychiatric clinic an average of 6 years before their FES had deficits in IQ when first seen but showed no additional deficit when followed up nearly 2 decades later.<sup>115</sup>

In accord with the above, individuals considered to be at clinical high risk for psychosis have been demonstrated to have significant cognitive deficits with those who eventually develop psychosis having greater deficits than those who do not.<sup>116</sup> However, studies by Keefe et al<sup>117</sup> and Becker et al<sup>118</sup> were not able to demonstrate any further deterioration in cognition in those at-risk subjects who

subsequently transitioned to psychosis. The potential for such studies to identify significant deterioration in cognition has been limited by their small sample sizes and their identification of at-risk subjects late in the prodromal phase.

## Conclusions

The notion that schizophrenia is by nature a progressive deteriorating illness was central to the concept of dementia praecox as originally outlined by Kraepelin.<sup>2</sup> When structural brain abnormalities and cognitive deficits were demonstrated in the late 1970s these were taken as confirming that the illness was indeed a dementia of the young.<sup>36</sup>

It is true that people with schizophrenia as a group show modest decreases in certain brain tissue volumes at the time of the FEP but much research suggests that these, at least in part, reflect neurodevelopmental abnormalities.<sup>119</sup> In addition, MRI studies in the last decade have suggested a “progressive” component that can be detected after illness onset.<sup>120</sup> However, the pathological nature of these changes remains unclear.<sup>121</sup> There is no direct evidence for a toxic effect of psychosis on brain tissue, and emerging evidence from human and animal studies suggests that these changes are in part consequent upon antipsychotic medication.<sup>57,58</sup> Furthermore, there is evidence that cannabis, alcohol, smoking, stress-related hypercortisolemia, and low physical activity also contribute to the changes in cortical and ventricular volumes observed over the course of schizophrenia. Together with the effects of antipsychotic medications, these factors appear to account for the majority of the so-called “progressive” brain changes. Their importance lies in the fact that at least some may be reversible.

The findings from neuropsychology consistently contradict the idea of schizophrenia as a progressive dementia. Cognitive deficits are present at a young age in some children who later develop schizophrenia together with slower cognitive development in a range of domains, which results in further divergence in cognitive ability by the time psychosis develops. However, there is no evidence that lasting cognitive decline occurs during the transition to psychosis or following its onset.

Thus, the idea that schizophrenia is a progressive brain disease is not supported by the weight of longitudinal neuroimaging and cognitive studies, and it is not consistent with what is now known about the clinical course of schizophrenia. It is important for optimum clinical care that the idea that underlying schizophrenia there exists an intrinsically malignant process be reconsidered. It has contributed to an undue pessimism among mental health professionals and their consequent alienation from sufferers and their representatives, who increasingly advocate for the “recovery model.”<sup>14,122</sup>

Furthermore, etiological and clinical research suggests that schizophrenia is not a discrete illness with a single

cause or course, rather it appears to be a syndrome with multiple interacting causes, both genetic and environmental, and a heterogeneous outcome.<sup>123</sup> Thus we can better conceive individuals diagnosed with schizophrenia as having a vulnerability to psychotic reactions to a range of biological<sup>124</sup> and social risk factors.<sup>125</sup> The greater the cumulative load of risk factors before onset, and also incurred subsequently, the more likely the individual is to have a poor outcome. Some individuals, especially those with developmental impairment, start their journey through illness with considerable impairment of their ability to cope with further stressors and show deterioration in their social functioning; others may start with less vulnerability but are exposed to repeated social adversities that prevent their recovery.

Rejecting the concept of schizophrenia as a progressive brain disease does not negate the serious and disabling problems that many patients with schizophrenia experience. No doubt, many patients experience a decline in many spheres of functioning. Further research is certainly required to determine whether there is an active period of developmental or degenerative changes that take place prior to the syndrome being expressed and diagnosed. However, it is important for patients, family members, clinicians, and the public more broadly to recognize that the deterioration that many patients experience over the long-term is not an inevitable part of the illness course. Sadly, many people with schizophrenia do not have access to the skilled mental health services and social supports that are needed for them to achieve recovery and a good quality of life. It is crucial to appreciate that the terrible social sequelae of schizophrenia such as homelessness, poverty, unemployment, hospitalization, and imprisonment are not the inevitable outcomes of a progressive brain disease but highlight the challenges we face in providing the needed services and supports, and in engaging ill people in models of care which they are likely to accept and appreciate.

## Funding

This work was supported by the Morgan Firestone Chair in Psychiatry at McMaster University.

## Acknowledgments

The authors have declared that there are no conflicts of interest in relation to the subject of this study.

## References

1. Prince M, Patel V, Saxena S, et al. No health without mental health. *Lancet*. 2007;370:859–877.
2. Jablensky A. Living in a Kraepelinian world: Kraepelin's impact on modern psychiatry. *Hist Psychiatry*. 2007;18:381–388.

3. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. *Biol Psychiatry*. 1999;46:729–739.
4. DeLisi LE. The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia. *Schizophr Bull*. 2008;34:312–321.
5. Andreasen NC, Nopoulos P, Magnotta V, Pierson R, Ziebell S, Ho BC. Progressive brain change in schizophrenia: a prospective longitudinal study of first-episode schizophrenia. *Biol Psychiatry*. 2011;70:672–679.
6. van Haren NE, Cahn W, Hulshoff Pol HE, Kahn RS. Schizophrenia as a progressive brain disease. *Eur Psychiatry*. 2008;23:245–254.
7. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. *Schizophr Bull*. 1991;17:325–351.
8. Malla AK, Bodnar M, Joober R, Lepage M. Duration of untreated psychosis is associated with orbital-frontal grey matter volume reductions in first episode psychosis. *Schizophr Res*. 2011;125:13–20.
9. Lieberman J, Jody D, Geisler S, et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. *Arch Gen Psychiatry*. 1993;50:369–376.
10. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. *Am J Psychiatry*. 2004;161:473–479.
11. Girgis RR, Phillips MR, Li X, et al. Clozapine v. chlorpromazine in treatment-naïve, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. *Br J Psychiatry*. 2011;199:281–288.
12. Liberman RP, Kopelowicz A, Ventura J, Gutkind D. Operational criteria and factors related to recovery from schizophrenia. *Int Rev Psychiatry*. 2002;14:256–272.
13. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. *Am J Psychiatry*. 2005;162:441–449.
14. Liberman RP, Kopelowicz A. Recovery from schizophrenia: a concept in search of research. *Psychiatr Serv*. 2005;56:735–742.
15. Lambert M, Naber D, Schacht A, et al. Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. *Acta Psychiatr Scand*. 2008;118:220–229.
16. Menezes NM, Arenovich T, Zipursky RB. A systematic review of longitudinal outcome studies of first-episode psychosis. *Psychol Med*. 2006;36:1349–1362.
17. Crumlish N, Whitty P, Clarke M, et al. Beyond the critical period: longitudinal study of 8-year outcome in first-episode non-affective psychosis. *Br J Psychiatry*. 2009;194:18–24.
18. Menezes NM, Malla AM, Norman RM, Archie S, Roy P, Zipursky RB. A multi-site Canadian perspective: examining the functional outcome from first-episode psychosis. *Acta Psychiatr Scand*. 2009;120:138–146.
19. Bertelsen M, Jeppesen P, Petersen L, et al. Course of illness in a sample of 265 patients with first-episode psychosis—five-year follow-up of the Danish OPUS trial. *Schizophr Res*. 2009;107:173–178.
20. Malla AK, Norman RM, Manchanda R, et al. Status of patients with first-episode psychosis after one year of phase-specific community-oriented treatment. *Psychiatr Serv*. 2002;53:458–463.
21. Addington J, Leriger E, Addington D. Symptom outcome 1 year after admission to an early psychosis program. *Can J Psychiatry*. 2003;48:204–207.
22. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. *Arch Gen Psychiatry*. 1999;56:241–247.
23. Gitlin M, Nuechterlein K, Subotnik KL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. *Am J Psychiatry*. 2001;158:1835–1842.
24. Boonstra G, Burger H, Grobbee DE, Kahn RS. Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial. *Int J Psychiatry Clin Pract*. 2011;15:128–134.
25. Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. *Arch Gen Psychiatry*. 1982;39:70–73.
26. McCreadie RG, Wiles D, Grant S, et al. The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group. *Acta Psychiatr Scand*. 1989;80:597–602.
27. Gaebel W, Riesbeck M, Wölwer W, et al. Relapse prevention in first-episode schizophrenia—maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. *J Clin Psychiatry*. 2011;72:205–218.
28. Harding CM, Brooks GW, Ashikaga T, Strauss JS, Breier A. The Vermont longitudinal study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. *Am J Psychiatry*. 1987;144:727–735.
29. Henry LP, Amminger GP, Harris MG, et al. The EPPIC follow-up study of first-episode psychosis: longer-term clinical and functional outcome 7 years after index admission. *J Clin Psychiatry*. 2010;71:716–728.
30. Harrison G, Hopper K, Craig T, et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. *Br J Psychiatry*. 2001;178:506–517.
31. van Os J, Wright P, Murray R. Follow-up studies of schizophrenia I: Natural history and non-psychopathological predictors of outcome. *Eur Psychiatry*. 1997;12(suppl 5):327s–341s.
32. Cohen P, Cohen J. The clinician's illusion. *Arch Gen Psychiatry*. 1984;41:1178–1182.
33. Kirch DG, Weinberger DR. Anatomical neuropathology in schizophrenia: postmortem findings. In: Nasrallah HA, Weinberger DR, eds. *Handbook of Schizophrenia, The Neurology of Schizophrenia*. Amsterdam: Elsevier; 1986:325–349.
34. Haug JO. Pneumoencephalographic studies in mental disease. *Acta Psychiatr Scand Suppl*. 1962;38:1–104.
35. Haug JO. Pneumoencephalographic evidence of brain atrophy in acute and chronic schizophrenic patients. *Acta Psychiatr Scand*. 1982;66:374–383.
36. Johnstone EC, Crow TJ, Frith CD, Husband J, Kreel L. Cerebral ventricular size and cognitive impairment in chronic schizophrenia. *Lancet*. 1976;2:924–926.
37. Reveley AM, Reveley MA, Clifford CA, Murray RM. Cerebral ventricular size in twins discordant for schizophrenia. *Lancet*. 1982;1:540–541.
38. Weinberger DR, Torrey EF, Neophytides AN, Wyatt RJ. Structural abnormalities in the cerebral cortex of chronic schizophrenic patients. *Arch Gen Psychiatry*. 1979;36:935–939.
39. Pfefferbaum A, Zipursky RB, Lim KO, Zatz LM, Stahl SM, Jernigan TL. Computed tomographic evidence for generalized sulcal and ventricular enlargement in schizophrenia. *Arch Gen Psychiatry*. 1988;45:633–640.

40. Zipursky RB, Lim KO, Sullivan EV, Brown BW, Pfefferbaum A. Widespread cerebral gray matter volume deficits in schizophrenia. *Arch Gen Psychiatry*. 1992;49:195–205.
41. Harvey I, Ron MA, Du Boulay G, Wicks D, Lewis SW, Murray RM. Reduction of cortical volume in schizophrenia on magnetic resonance imaging. *Psychol Med*. 1993;23:591–604.
42. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. *Schizophr Res*. 2001;49:1–52.
43. Luchins DJ, Meltzer HY. A comparison of CT findings in acute and chronic ward schizophrenics. *Psychiatry Res*. 1986;17:7–14.
44. Gur RE, Turetsky BI, Bilker WB, Gur RC. Reduced gray matter volume in schizophrenia. *Arch Gen Psychiatry*. 1999;56:905–911.
45. Zipursky RB, Lambe EK, Kapur S, Mikulis DJ. Cerebral gray matter volume deficits in first episode psychosis. *Arch Gen Psychiatry*. 1998;55:540–546.
46. Lim KO, Tew W, Kushner M, Chow K, Matsumoto B, DeLisi LE. Cortical gray matter volume deficit in patients with first-episode schizophrenia. *Am J Psychiatry*. 1996;153:1548–1553.
47. Cahn W, Hulshoff Pol HE, Lems EB, et al. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. *Arch Gen Psychiatry*. 2002;59:1002–1010.
48. de Castro-Mangano P, Mechelli A, Soutullo C, et al. Structural brain abnormalities in first-episode psychosis: differences between affective psychoses and schizophrenia and relationship to clinical outcome. *Bipolar Disord*. 2011;13:545–555.
49. Mitelman SA, Brickman AM, Shihabuddin L, et al. A comprehensive assessment of gray and white matter volumes and their relationship to outcome and severity in schizophrenia. *Neuroimage*. 2007;37:449–462.
50. Staal WG, Hulshoff Pol HE, Kahn RS. Outcome of schizophrenia in relation to brain abnormalities. *Schizophr Bull*. 1999;25:337–348.
51. Staal WG, Hulshoff Pol HE, Schnack HG, van Haren NE, Seifert N, Kahn RS. Structural brain abnormalities in chronic schizophrenia at the extremes of the outcome spectrum. *Am J Psychiatry*. 2001;158:1140–1142.
52. Milev P, Ho BC, Arndt S, Nopoulos P, Andreasen NC. Initial magnetic resonance imaging volumetric brain measurements and outcome in schizophrenia: a prospective longitudinal study with 5-year follow-up. *Biol Psychiatry*. 2003;54:608–615.
53. Bellani M, Dusi N, Brambilla P. Longitudinal imaging studies in schizophrenia: the relationship between brain morphology and outcome measures. *Epidemiol Psichiatr Soc*. 2010;19:207–210.
54. Keshavan MS, Berger G, Zipursky RB, Wood SJ, Pantelis C. Neurobiology of early psychosis. *Br J Psychiatry Suppl*. 2005;48:s8–18.
55. Olabi B, Ellison-Wright I, McIntosh AM, Wood SJ, Bullmore E, Lawrie SM. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. *Biol Psychiatry*. 2011;70:88–96.
56. Ho BC, Andreasen NC, Nopoulos P, Arndt S, Magnotta V, Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. *Arch Gen Psychiatry*. 2003;60:585–594.
57. Moncrieff J, Leo J. A systematic review of the effects of antipsychotic drugs on brain volume. *Psychol Med*. 2010;40:1409–1422.
58. Navari S, Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. *Psychol Med*. 2009;39:1763–1777.
59. Lieberman JA, Tollefson GD, Charles C, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. *Arch Gen Psychiatry*. 2005;62:361–370.
60. Joobar R, Schmitz N, Malla A, Sengupta S, Karma S. Is olanzapine a brain-sparing medication? *Arch Gen Psychiatry*. 2006;63:1292.
61. Ho BC, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. *Arch Gen Psychiatry*. 2011;68:128–137.
62. Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. *Neuropsychopharmacology*. 2005;30:1649–1661.
63. Vernon AC, Natesan S, Modo M, Kapur S. Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. *Biol Psychiatry*. 2011;69:936–944.
64. Vernon AC, Natesan S, Crum WR, et al. Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation. *Biol Psychiatry*. 2012;71:855–863.
65. Schaufelberger MS, Lappin JM, Duran FL, et al. Lack of progression of brain abnormalities in first-episode psychosis: a longitudinal magnetic resonance imaging study. *Psychol Med*. 2011;41:1677–1689.
66. Yücel M, Solowij N, Respondek C, et al. Regional brain abnormalities associated with long-term heavy cannabis use. *Arch Gen Psychiatry*. 2008;65:694–701.
67. Rais M, Cahn W, Van Haren N, et al. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. *Am J Psychiatry*. 2008;165:490–496.
68. Martín-Santos R, Fagundo AB, Crippa JA, et al. Neuroimaging in cannabis use: a systematic review of the literature. *Psychol Med*. 2010;40:383–398.
69. Gallinat J, Meisenzahl E, Jacobsen LK, et al. Smoking and structural brain deficits: a volumetric MR investigation. *Eur J Neurosci*. 2006;24:1744–1750.
70. Welch KA, McIntosh AM, Job DE, et al. The impact of substance use on brain structure in people at high risk of developing schizophrenia. *Schizophr Bull*. 2011;37:1066–1076.
71. Mathalon DH, Pfefferbaum A, Lim KO, Rosenbloom MJ, Sullivan EV. Compounded brain volume deficits in schizophrenia-alcoholism comorbidity. *Arch Gen Psychiatry*. 2003;60:245–252.
72. Pfefferbaum A, Lim KO, Zipursky RB, et al. Brain gray and white matter volume loss accelerates with aging in chronic alcoholics: a quantitative MRI study. *Alcohol Clin Exp Res*. 1992;16:1078–1089.
73. Pfefferbaum A, Sullivan EV, Rosenbloom MJ, Mathalon DH, Lim KO. A controlled study of cortical gray matter and ventricular changes in alcoholic men over a 5-year interval. *Arch Gen Psychiatry*. 1998;55:905–912.
74. Stone JM, Bhattacharyya S, Barker GJ, McGuire PK. Substance use and regional gray matter volume in individuals at high risk of psychosis. *Eur Neuropsychopharmacol*. 2012;22:114–122.
75. Colcombe SJ, Erickson KI, Scalf PE, et al. Aerobic exercise training increases brain volume in aging humans. *J Gerontol A Biol Sci Med Sci*. 2006;61:1166–1170.

76. Black JE, Isaacs KR, Anderson BJ, Alcantara AA, Greenough WT. Learning causes synaptogenesis, whereas motor activity causes angiogenesis, in cerebellar cortex of adult rats. *Proc Natl Acad Sci USA*. 1990;87:5568–5572.
77. van Praag H, Christie BR, Sejnowski TJ, Gage FH. Running enhances neurogenesis, learning, and long-term potentiation in mice. *Proc Natl Acad Sci USA*. 1999;96:13427–13431.
78. Pajonk FG, Wobrock T, Gruber O, et al. Hippocampal plasticity in response to exercise in schizophrenia. *Arch Gen Psychiatry*. 2010;67:133–143.
79. Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. *Arch Gen Psychiatry*. 2000;57:925–935.
80. Starkman MN, Giordani B, Gebarski SS, Berent S, Schork MA, Schteingart DE. Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease. *Biol Psychiatry*. 1999;46:1595–1602.
81. Heinz ER, Martinez J, Haenggeli A. Reversibility of cerebral atrophy in anorexia nervosa and Cushing's syndrome. *J Comput Assist Tomogr*. 1977;1:415–418.
82. Mondelli V, Cattaneo A, Belvederi Murri M, et al. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. *J Clin Psychiatry*. 2011;72:1677–1684.
83. Bangalore SS, Goradia DD, Nutche J, Diwadkar VA, Prasad KM, Keshavan MS. Untreated illness duration correlates with gray matter loss in first-episode psychoses. *Neuroreport*. 2009;20:729–734.
84. Lappin JM, Morgan K, Morgan C, et al. Gray matter abnormalities associated with duration of untreated psychosis. *Schizophr Res*. 2006;83:145–153.
85. Madsen AL, Karle A, Rubin P, Cortsen M, Andersen HS, Hemmingsen R. Progressive atrophy of the frontal lobes in first-episode schizophrenia: interaction with clinical course and neuroleptic treatment. *Acta Psychiatr Scand*. 1999;100:367–374.
86. Takahashi T, Suzuki M, Tanino R, et al. Volume reduction of the left planum temporale gray matter associated with long duration of untreated psychosis in schizophrenia: a preliminary report. *Psychiatry Res*. 2007;154:209–219.
87. Boonstra G, Cahn W, Schnack HG, et al. Duration of untreated illness in schizophrenia is not associated with 5-year brain volume change. *Schizophr Res*. 2011;132:84–90.
88. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. *Neuropsychology*. 1998;12:426–445.
89. Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. *Am J Psychiatry*. 2000;157:549–559.
90. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? *Am J Psychiatry*. 1996;153:321–330.
91. Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. *Am J Psychiatry*. 2011;168:472–485.
92. Crespo-Facorro B, Barbadillo L, Pelayo-Terán JM, Rodríguez-Sánchez JM. Neuropsychological functioning and brain structure in schizophrenia. *Int Rev Psychiatry*. 2007;19:325–336.
93. Sullivan EV, Shear PK, Lim KO, Zipursky RB, Pfefferbaum A. Cognitive and motor impairments are related to gray matter volume deficits in schizophrenia. *Biol Psychiatry*. 1996;39:234–240.
94. Hartberg CB, Lawyer G, Nyman H, et al. Investigating relationships between cortical thickness and cognitive performance in patients with schizophrenia and healthy adults. *Psychiatry Res*. 2010;182:123–133.
95. Sanfilippo M, Lafargue T, Rusinek H, et al. Cognitive performance in schizophrenia: relationship to regional brain volumes and psychiatric symptoms. *Psychiatry Res*. 2002;116:1–23.
96. Bozikas VP, Andreou C. Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature. *Aust N Z J Psychiatry*. 2011;45:93–108.
97. Szöke A, Trandafir A, Dupont ME, Méary A, Schürhoff F, Leboyer M. Longitudinal studies of cognition in schizophrenia: meta-analysis. *Br J Psychiatry*. 2008;192:248–257.
98. Seidman LJ, Buka SL, Goldstein JM, Tsuang MT. Intellectual decline in schizophrenia: evidence from a prospective birth cohort 28 year follow-up study. *J Clin Exp Neuropsychol*. 2006;28:225–242.
99. Lewandowski KE, Cohen BM, Ongur D. Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. *Psychol Med*. 2011;41:225–241.
100. Zanelli J, Reichenberg A, Morgan K, et al. Specific and generalized neuropsychological deficits: a comparison of patients with various first-episode psychosis presentations. *Am J Psychiatry*. 2010;167:78–85.
101. Censits DM, Ragland JD, Gur RC, Gur RE. Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study. *Schizophr Res*. 1997;24:289–298.
102. Leeson VC, Sharma P, Harrison M, Ron MA, Barnes TR, Joyce EM. IQ trajectory, cognitive reserve, and clinical outcome following a first episode of psychosis: a 3-year longitudinal study. *Schizophr Bull*. 2011;37:768–777.
103. Keefe RS, Sweeney JA, Gu H, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. *Am J Psychiatry*. 2007;164:1061–1071.
104. Goldberg TE, Keefe RS, Goldman RS, Robinson DG, Harvey PD. Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. *Neuropsychopharmacology*. 2010;35:1053–1062.
105. Davidson M, Harvey P, Welsh KA, Powchik P, Putnam KM, Mohs RC. Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenic patients and patients with Alzheimer's disease. *Am J Psychiatry*. 1996;153:1274–1279.
106. Harvey PD, Silverman JM, Mohs RC, et al. Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. *Biol Psychiatry*. 1999;45:32–40.
107. Jones P, Rodgers B, Murray R, Marmot M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. *Lancet*. 1994;344:1398–1402.
108. David AS, Malmberg A, Brandt L, Allebeck P, Lewis G. IQ and risk for schizophrenia: a population-based cohort study. *Psychol Med*. 1997;27:1311–1323.
109. Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. *Am J Psychiatry*. 1999;156:1328–1335.
110. Cannon TD, Bearden CE, Hollister JM, Rosso IM, Sanchez LE, Hadley T. Childhood cognitive functioning in schizophrenia patients and their unaffected siblings: a prospective cohort study. *Schizophr Bull*. 2000;26:379–393.

111. Woodberry KA, Giuliano AJ, Seidman LJ. Premorbid IQ in schizophrenia: a meta-analytic review. *Am J Psychiatry*. 2008;165:579–587.
112. Khandaker GM, Barnett JH, White IR, Jones PB. A quantitative meta-analysis of population-based studies of premorbid intelligence and schizophrenia. *Schizophr Res*. 2011;132:220–227.
113. Bilder RM, Reiter G, Bates J, et al. Cognitive development in schizophrenia: follow-back from the first episode. *J Clin Exp Neuropsychol*. 2006;28:270–282.
114. Reichenberg A, Caspi A, Harrington H, et al. Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. *Am J Psychiatry*. 2010;167:160–169.
115. Russell AJ, Munro JC, Jones PB, Hemsley DR, Murray RM. Schizophrenia and the myth of intellectual decline. *Am J Psychiatry*. 1997;154:635–639.
116. Fusar-Poli P, Deste G, Smieskova R, et al. Cognitive functioning in prodromal psychosis: a meta-analysis. *Arch Gen Psychiatry*. 2012;69:562–571.
117. Keefe RS, Perkins DO, Gu H, Zipursky RB, Christensen BK, Lieberman JA. A longitudinal study of neurocognitive function in individuals at-risk for psychosis. *Schizophr Res*. 2006;88:26–35.
118. Becker HE, Nieman DH, Wiltink S, et al. Neurocognitive functioning before and after the first psychotic episode: does psychosis result in cognitive deterioration? *Psychol Med*. 2010;40:1599–1606.
119. Murray RM, Lewis SW. Is schizophrenia a neurodevelopmental disorder? *Br Med J*. 1987;295:681–682.
120. Hulshoff Pol HE, Kahn RS. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. *Schizophr Bull*. 2008;34:354–366.
121. Weinberger DR, McClure RK. Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain? *Arch Gen Psychiatry*. 2002;59:553–558.
122. Bellack AS. Scientific and consumer models of recovery in schizophrenia: concordance, contrasts, and implications. *Schizophr Bull*. 2006;32:432–442.
123. van Os J, Kapur S. Schizophrenia. *Lancet*. 2009;374:635–645.
124. Di Forti M, Lappin JM, Murray RM. Risk factors for schizophrenia—all roads lead to dopamine. *Eur Neuropsychopharmacol*. 2007;17(suppl 2):S101–S107.
125. Morgan C, Charalambides M, Hutchinson G, Murray RM. Migration, ethnicity, and psychosis: toward a sociodevelopmental model. *Schizophr Bull*. 2010;36:655–664.